Sai Parenterals Reports Q4 and Nine-Month Financial Results

The company announced the approval of its unaudited and audited financial results for the quarter and nine months ended March 31, 2026, during its board meeting held on May 23, 2026. The company reported a total income of Rs 124.59 crore for the nine-month period, reflecting a 12.4% increase from the previous year. Revenue from operations stood at Rs 120.27 crore, driven by growth in branded generic formulations and contract development and manufacturing organisation (CDMO) services. The audited results also highlighted a profit after tax of Rs 10.28 crore, with earnings per share (EPS) of Rs 0.38 per share. These figures were prepared in compliance with SEBI regulations and Indian Accounting Standards, marking the first submission of such data under Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Key financial metrics revealed a 10.00% profit before tax for the nine-month period, with total expenses amounting to Rs 77.11 crore. The company’s cost of materials consumed rose to Rs 56.53 crore, while depreciation and amortisation expenses reached Rs 86.70 crore. the audited financial statements showed an unmodified opinion from the statutory auditors, reinforcing the reliability of the reported figures. The unaudited results for the quarter ended December 31, 2025, indicated a revenue of Rs 38.48 crore, with a profit before tax of Rs 16.25 crore. These numbers underscore the company’s operational efficiency despite challenges in inventory management, which saw a change in inventories of finished goods and stock-in-trade contributing to a Rs 26.79 crore impact on the nine-month results.

The company disclosed a significant acquisition activity, investing AUD 2,200 million (approximately Rs 176 crore at current exchange rates) to acquire a majority stake in Nourmed Life Sciences Limited (UK). This strategic move was completed through its wholly owned subsidiary, Sai Parenterals Pte Limited, with an additional equity investment of AUD 4 million in November 2025. The acquisition aligns with Sai Parenterals’ focus on expanding its global footprint in the pharmaceutical sector. The financial statements also noted no exceptional or extraordinary items during the reviewed period, ensuring a clean profit and loss account. The company’s earnings per share (EPS) remained stable at Rs 0.38 per share, with no annualisation applied to the quarterly figures, reflecting consistent performance across reporting periods.

Sai Parenterals emphasized compliance with recent labour code implementations, including the Code on Wages, 2019, and the Code on Social Security, 2020. The management assessed that these changes had no material impact on the financial statements, ensuring adherence to regulatory requirements without affecting profitability. The company’s business model, centered on branded generics and CDMO services, was highlighted as its sole reportable segment under Ind AS 108. This focus allows the company to streamline operations and allocate resources effectively. the audited results for the year ended March 31, 2026, included a detailed breakdown of tax expenses, with current tax at Rs 5.95 crore and deferred tax at Rs 53.17 crore. The total comprehensive income for the period was Rs 181 crore, reflecting the company’s financial health. The board’s approval of these results paves the way for potential initial public offerings (IPOs), as the company has filed a draft red herring prospectus (DRHP) with regulatory authorities, signaling future growth opportunities.

Disclaimer: This article is based on company filings submitted to the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE) and is for informational purposes only. It does not constitute investment advice or a recommendation. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.